Marine Drugs

Marine toxins are natural compounds produced by a variety of marine organisms, including microalgae, bacteria, and macroalgae [...]

This scoping review mapped the available evidence on marine algae-derived bioactive compounds, focusing on their biological activities related to collagen stabilization, matrix metalloproteinase (MMP) inhibition, and enamel remineralization in dental hard tissues. Four electronic databases (PubMed, Scopus, Embase, and Web of Science) were systematically searched following a predefined protocol. Original experimental studies involving human or animal dental hard tissues were included. Nine studies met the inclusion criteria. Brown algal derivatives, including fucoxanthin, fucosterol, and phloroglucinol, exhibited significant MMP inhibition and, in selected compounds, collagen cross-linking, contributing to enhanced mechanical properties and improved stability of collagen-rich matrices. In contrast, red algae extracts such as Lithothamnion calcareum primarily promoted enamel remineralization, achieving surface microhardness recovery comparable to or superior to 0.05% sodium fluoride. Alginate, a brown algae-derived polysaccharide, also demonstrated functional potential as a scaffold biomaterial through strong hydroxyapatite adsorption and suitability for three-dimensional scaffold fabrication. Overall, marine algae-derived compounds demonstrate biologically relevant activities that modulate collagen stability, enzymatic function, and mineral deposition processes. These findings highlight the pharmacological potential of marine bioactive compounds, with dental hard tissues representing a primary application context. However, further validation using clinically relevant models is required.

Marine ecosystems have yielded a remarkable diversity of bioactive metabolites with relevance for antiviral drug discovery. This article reviews recent advances in marine-derived compounds investigated as anti-HIV agents. Metabolites, such as sulfated polysaccharides, lectins, alkaloids, and terpenoids, display inhibitory activity across multiple stages of the HIV life cycle, including viral entry, reverse transcription, integration, and maturation. From sponge-inspired development of AZT to the application of Griffithin in clinical trials for the prophylaxis of the HIV infection, recent discoveries showcase the chemical diversity of marine ecosystems and validate their utility as hit and compound sources in drug discovery. We highlight possible mechanisms of action, as well as translational hurdles from research to clinical trials. Overall, marine biodiversity represents a valuable and underexploited reservoir for the development of novel HIV therapeutics.